

MODULATING PRODUCTION OF  
PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE

5

This research was supported in part by U.S. Government funds (U.S. Public Health Service grant numbers AI38436 and AI44231), and the U.S. Government may therefore have certain rights in the invention.

10

BACKGROUND OF THE INVENTION

The invention relates broadly to production of capsular polysaccharide material from streptococcal organisms and to production of vaccines using such material.

15  
20  
25  
30

*Streptococcus pneumoniae*, sometimes designated pneumococcus, is generally a commensal organism colonizing the mucosal surface of the human nasopharynx. When host factors allow the organism access to the lower respiratory tract, a vigorous inflammatory response ensues, leading to a dense consolidation as alveolar air spaces fill with exudate. This condition is commonly referred to as pneumonia (Tuomanen et al., 1995). The most serious manifestation of pneumococcal infection is bacteremia, which can be complicated by sepsis, meningitis, or both. Bacteremia in adults is usually a complication of pneumonia (Raz et al., 1997).

25

The ability of the pneumococcus to resist the major mechanism of clearance of the organism from the bloodstream (i.e. opsonophagocytosis) requires expression of the major virulence factor of the organism, which is a polysaccharide capsule (Avery et al., 1931; Watson et al., 1990). Pneumococci are capable of synthesizing no fewer than 90 structurally unique capsular polysaccharides (CPSs).

30

Pneumococcal CPS exhibits anti-phagocytic properties and inhibits adherence to host cells, a critical step in carriage (i.e. spread of the organism from one infected, but not necessarily symptomatic, individual to another) and possibly later aspects in the pathogenesis of disease (Ring et al., 1998). Similar findings in other encapsulated species (e.g. *Haemophilus influenzae*, *Neisseria meningitidis*, *Streptococcus pyogenes*, and *Streptococcus agalactiae*) has led to an appreciation of how amounts of CPS must be temporally varied to allow both adhesive interactions with host cells and resistance to humoral immunity (Hammerschmidt et al., 1996; Levin et al., 1998; Schragar et al., 1996; Sellin et al., 1995; St. Geme III et al., 1991).

Even within a single strain, the amount of CPS expressed by *S. pneumoniae* varies. The regulatory mechanism(s) which modulate CPS expression have not previously been well understood. Most pneumococcal isolates undergo phenotypic variation between at least two forms, which can be distinguished by colony opacity (Weiser, 1998; Weiser et al., 1994). Opaque (O) colony forms differ from transparent (T) variants of the same strain in the amount of CPS that is synthesized, O-form colonies generally making a greater amount of CPS (Kim et al., 1998).

Relatively minor differences in the amount of CPS made by a pneumococcal variant can have a major impact on virulence (MacLeod et al., 1950). The 1.2 to 5.6-fold higher quantities of CPS produced by O-form colonies, compared to T-form colonies, correlates with increased resistance of pneumococcal cells to opsonophagocytosis using immune serum (Kim et al., 1999). In a murine model of systemic infection, only the O variant of several pneumococcal strains caused sepsis (Kim et al., 1998). In contrast, the T form expresses higher amounts of the other cell surface polysaccharide, teichoic acid. Pneumococcal cell-wall teichoic acid is covalently linked to CPS and contains an unusual host-like constituent, phosphorylcholine. This polysaccharide contributes to adherence of pneumococcal cells to epithelial cells via the receptor for platelet activating factor (Cundell et al., 1995; Cundell et al., 1995; Kim et al., 1998). The T form also exhibits an altered distribution of cell surface choline-binding proteins, including CbpA, which acts to promote adherence and colonization (Rosenow et al., 1997). During carriage in an infant rat model, there is selection for pneumococcal variants which exhibit the T, rather than O, phenotype (Weiser et al., 1994). These observations suggests that pneumococci vary between a form (i.e. the T-form) which exhibits greater adherence and carriage, and a non-adherent form (i.e. the O-form) which is better adapted to survival in invasive infection.

Identification of the CPSs expressed by a pneumococcus forms the basis of serotyping, a diagnostic procedure used for differentiating *S. pneumoniae* variants. Because different variants can exhibit different physiological properties (e.g. susceptibility to antimicrobial agents or characteristic rate of onset or progression of pneumonia), ability to differentiate pneumococcal variants is medically advantageous. Furthermore, because the ability of the human (or other vertebrate) immune system to recognize and attack pneumococcal variants depends on its ability to specifically recognize the CPS of each variant, ability to obtain pneumococcal variant-specific CPS significantly affects

development of therapeutic and preventive methods and compositions for alleviating disorders associated with pneumococcal infection. For example, known pneumococcal vaccines comprise CPS obtained from numerous pneumococcal variants.

There remains a significant need for diagnostic, prognostic, therapeutic, and preventive compositions and methods useful with disorders associated with pneumococcal infection. Many of these compositions and methods comprise, employ, or rely for their development on isolated pneumococcal CPS. Previously known methods for isolating CPS from pneumococci are generally characterized by low yield. The present invention includes a method of improving the yield of CPS that can be obtained from a pneumococcal variant, and enhances production and use of diagnostic, prognostic, therapeutic, and preventive compositions and methods pertaining to pneumococcal infections.

#### BRIEF SUMMARY OF THE INVENTION

The invention relates to an improvement in a method of producing capsular polysaccharide from a pneumococcus by maintaining the pneumococcus in a growth medium. In one aspect, the improvement comprises maintaining a gas having a sub-atmospheric concentration of oxygen in contact with the growth medium (e.g. an oxygen concentration not greater than about 16% or not greater than about 0.1%). The pneumococcus can be an organism of the genus *Streptococcus*, such as an organism of the species *Streptococcus pneumoniae* (e.g. one of *S. pneumoniae* variants 6A, 6B, 18C, and 9V). In another aspect, the improvement comprises maintaining a gas having a super-atmospheric concentration (e.g. at least about 3% or 10%) of carbon dioxide in contact with the growth medium. In a third aspect, the improvement comprises maintaining a gas having both a super-atmospheric concentration of carbon dioxide and a sub-atmospheric concentration of oxygen in contact with the growth medium. In still another aspect, the improvement comprises maintaining the carbon dioxide concentration of the growth medium at a level at least equal to the concentration of carbon dioxide in the same growth medium equilibrated at the same temperature with a gas comprising 5% carbon dioxide.

The invention also relates to a method of alleviating a pneumococcal infection in an animal. This method comprises maintaining the animal (e.g. at least the lungs of the animal) in contact with a gas having a super-atmospheric concentration (e.g. 25%, 50%, or

100%) of oxygen. Examples of infections which can be alleviated in this method include pneumonia, bacteremia, sepsis, and meningitis.

The invention further relates to a method of making an immunogenic preparation for administration to an animal at risk for developing a pneumococcal infection.

5 This method comprises maintaining pneumococcal cells in a growth medium having an oxygen content lower than the same medium equilibrated at the same temperature with normal air and isolating capsular polysaccharide produced by the cells from the cells. The isolated polysaccharide constitutes the immunogenic preparation.

10 The invention still further relates to a method of producing pneumococcal polysaccharide. This method comprises maintaining pneumococcal cells in a growth medium having an oxygen content lower than the same medium equilibrated at the same temperature with normal air, for example, a medium substantially devoid of oxygen. In one embodiment, the medium has a carbon dioxide content which is greater than the same medium equilibrated at the same temperature with normal air, for example, a medium saturated with carbon  
15 dioxide or a medium comprising a carbonate or bicarbonate salt.

The invention includes a method of assessing whether a test compound is useful for alleviating a pneumococcal infection in an animal. This method comprises comparing

- 20 (a) the degree of phosphorylation of CpsD in pneumococcal cells maintained in the presence of the test compound and  
(b) the degree of phosphorylation of CpsD in the same type of cells maintained in the absence of the test compound.

If the degree of phosphorylation of CpsD in the cells maintained in the presence of the test compound is less than the degree of phosphorylation of CpsD in the cells maintained in the  
25 absence of the test compound, then the test compound is useful for alleviating the infection. The degree of phosphorylation of CpsD can, for example, be assessed by assessing the number of phosphorylated tyrosine residues present in CpsD or by assessing the fraction of CpsD having at least one phosphorylated tyrosine residue.

#### 30 BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1**, comprising Figures 1Ai-1Avi and 1Bi-1Bvi, is a series of images which indicate the effect of environmental oxygen and carbon dioxide concentration on

colony morphology and capsule size, as assessed using the Quellung reaction. Opaque (Figures 1Ai, 1Aii, 1Aiii, 1Bi, 1Bii, and 1Biii) and transparent (Figures 1Aiv, 1Av, 1Avi, 1Biv, 1Bv, and 1Bvi) variants of a type 6A pneumococcal isolate were grown on T nutrient agar supplemented with catalase for 16 hours at 37°C under atmospheric conditions (Figures 1Ai, 1Aiv, 1Bi, and 1Biv), under atmospheric conditions comprising an increased carbon dioxide concentration (Figures 1Aii, 1Av, 1Bii, and 1Bv), and under anaerobic conditions comprising an increased carbon dioxide concentration (Figures 1Aiii, 1Avi, 1Biii, and 1Bvi). Colonies in the images in Figures 1Ai-1Avi were visualized using oblique, transmitted illumination, and are shown at a magnification of 56×. Capsular material in the images in Figures 1Bi-1Bvi were visualized using the Quellung reaction and type specific antisera, and are shown at a magnification of 4000×.

**Figure 2**, comprising Figures 2A-2D, is a quartet of bar graphs which depict the effects of environmental oxygen and carbon dioxide concentration and opacity phenotype on CPS production, on a per unit protein basis, as assessed using a capture ELISA. Opaque (Figures 2Ai, 2Bi, 2Ci, and 2Di) and transparent (Figures 2Aii, 2Bii, 2Cii, and 2Dii) variants of isolates of the four pneumococcal types (variant 6B in Figures 2Ai and 2Aii; variant 6A in Figures 2Bi and 2Bii; variant 18C in Figures 2Ci and 2Cii; variant 9V in Figures 2Di and 2Dii) were grown to mid-log phase (solid bars) or stationary phase (stippled bars) at oxygen and carbon dioxide concentrations indicated above the graphs. CPS production was determined in sonicated cell pellets and in culture supernatants (hatched bars), and is expressed relative to the quantity of total cellular protein. "\*" indicates that this variant did not grow under this condition. Values represent the mean of two separate experiments in duplicate.

**Figure 3**, comprising Figures 3A and 3B, is a pair of images which depict the effects of environmental oxygen and carbon dioxide concentration and opacity phenotype on tyrosine phosphorylation of CpsD in Western analysis. Whole cell lysates of O (lanes 1-4) and T (lanes 5-8) forms of pneumococcal variant P303 were removed after growth on solid medium and adjusted to equal density. The image in Figure 3A depicts proteins in these samples which were separated by SDS-PAGE, transferred to a membrane, and immunoblotted with a monoclonal antibody designated 4G10, which binds specifically with phosphorylated tyrosine. The image in Figure 3B depicts duplicate membranes which were

immunoblotted using antisera raised against whole pneumococci in order to demonstrate equal loading. Growth conditions corresponding to the cells lysed and applied to lanes were as follows: in lanes 1 and 5, <0.1% O<sub>2</sub> / 10% CO<sub>2</sub>; in lanes 2 and 6, 16% O<sub>2</sub> / 3% CO<sub>2</sub>; in lanes 3 and 7, 21% O<sub>2</sub> / <0.1% CO<sub>2</sub>; and in lanes 4 and 8, 19% O<sub>2</sub> / 10% CO<sub>2</sub>. The arrow in Figure 3A indicates the location of the 25 kD CpsD band. Size markers are in kilodaltons.

Figure 4 is an image which depicts the effects of environmental oxygen and carbon dioxide concentrations and opacity phenotype on transcription of *cpsD*, as assessed by Northern analysis. Total RNA obtained from O (Lanes 1 and 2) or T (Lanes 3 and 4) forms of pneumococcal variant P303 was separated on a formamide gel and probed using a radio-labeled fragment of *cpsD* obtained from a serotype 4 pneumococcus. Bacteria from which RNA was isolated were grown under <0.1% O<sub>2</sub> / 10% CO<sub>2</sub> (Lanes 1 and 3) or under 21% O<sub>2</sub> / <0.1% CO<sub>2</sub> (Lanes 2 and 4). Size markers are RNA standards in kilodaltons.

## DETAILED DESCRIPTION OF THE INVENTION

The invention relates to the discovery by the inventor that the amount of capsular polysaccharide (CPS) produced by pneumococci can be modulated by controlling the oxygen and carbon dioxide content of the medium in which they are maintained. It has also been discovered by the inventor that CPS production in *Streptococcus pneumoniae* is modulated by the presence of CpsD protein and by the post-translational modification of this protein. Based on these discoveries, the present invention includes methods for modulating CPS production by pneumococci (e.g. for use in production of anti-pneumococcal vaccines and other immunogenic preparations), methods for alleviating pneumococcal infections, and methods of identifying agents useful for alleviating pneumococcal infections.

### Definitions

As used herein, each of the following terms has the meaning associated with it in this section.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

"Normal" air refers to a gas having approximately the average content of the atmosphere at a selected location, without regard to the humidity (i.e. on a dry basis). The

average content of the atmosphere is about 78% N<sub>2</sub>, 21% O<sub>2</sub>, 1% Ar, and less than 0.04% each of CO<sub>2</sub>, H<sub>2</sub>, He, Ne, Kr, and Xe.

### Description

5 It has been discovered that production of capsular polysaccharide (CPS) by pneumococci is influenced by the presence and concentration of oxygen and carbon dioxide present in the cells' environment. In particular, production of CPS increases as the oxygen content of the environment decreases; production of CPS also increases as the carbon dioxide content of the environment increases. Although these observations have been made using cultures of  
10 *Streptococcus pneumoniae*, they can also be applied to organisms which exhibit capsule and capsule gene properties similar to pneumococci, such as other *Streptococcus* species (e.g. *Streptococcus agalactiae*), to other encapsulated organisms such as *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Acinetobacter johnsonii*, and organisms which exhibit phenotypic similarity, genotypic similarity, or both, to one or more of these. When the organism is *Streptococcus pneumoniae*, it can be any known or hereafter discovered variant thereof, including variants characterized by the identity of their CPS, such as one of variants  
15 6A, 6B, 18C, and 9V.

These observations can be used in conjunction with any known method of culturing pneumococci, or with any method hereafter developed, to increase (or decrease, if  
20 desired) production of CPS by pneumococci cultured by such methods. The invention includes a method of increasing the yield of CPS obtained by culturing a pneumococcus according to a known method. The improved method involves decreasing the oxygen content of the medium in or on which the pneumococcus is maintained, relative to the oxygen content which normally occurs in the medium during culture of the pneumococcus. For example, it is  
25 common to culture pneumococcus on a gelatinous or semi-solid medium or in a liquid medium, wherein the medium is maintained in contact with filtered (or otherwise sterilized) normal air.

Production of CPS by pneumococci can be increased by decreasing (on a dry basis) the oxygen content of the gas with which the medium is maintained in contact. The  
30 degree to which the oxygen content is decreased is not critical, but, generally speaking, the greater the decrease in oxygen content is, the greater the increased yield of CPS will be. The oxygen content of the gas is preferably <16%, or is decreased to the point that the gas is

substantially anaerobic (e.g. such that it contains  $<0.1\%$   $O_2$ ). The manner in which the oxygen content of the gas is decreased is not critical. Convenient methods of reducing the oxygen content of the gas below the oxygen content of normal air include flushing the culture vessel (at least initially, but alternatively intermittently, periodically, or continuously) with a gas having the desired oxygen content. For example, a culture vessel can be flushed with a gas mixture comprising about 71%  $N_2$ , 19%  $O_2$ , and 10 %  $CO_2$ , or with a mixture comprising 95% Ar and 5%  $CO_2$ .

Production of CPS by pneumococci can also be increased by increasing the carbon dioxide content of the gas with which the medium on or in which the pneumococci are maintained is contacted. The degree to which the carbon dioxide content of the gas is increased is not critical, but, generally speaking, the greater the increase in carbon dioxide content is, the greater the increased yield of CPS will be. The carbon dioxide content of the gas is preferably at least about 5%, or at least about 10%, although it can be so high that the culture medium is saturated with carbon dioxide. As discussed above, the desired carbon dioxide content can be achieved by flushing the vessel in which the pneumococci are cultured with a gas having the desired carbon dioxide content. Alternatively, carbon dioxide can be provided to the medium by incorporating a carbonate or bicarbonate salt into the medium or by adding such as salt to the medium.

The invention includes methods of increasing CPS production by pneumococci by increasing the carbon dioxide content of the medium in which the pneumococci are maintained, by increasing the carbon dioxide content of a gas which contacts that medium, by decreasing the oxygen content of that medium, by decreasing the oxygen content of a gas which contacts that medium, or any combination of these. In one embodiment, the  $O_2/CO_2$  content of the medium (or of a gas in contact with the medium) can be adjusted so as to maximize the yield of pneumococcal cells during one phase, and then can be re-adjusted to maximize production of CPS during a second phase.

Decreasing the oxygen content of the gas which contacts the medium causes a decrease in the oxygen content of the medium on or in which the pneumococcus is maintained, owing to equilibration of dissolved and non-dissolved gas. Changing the carbon dioxide content of the gas has a similar effect. The rapidity with which the gas dissolved in the medium and non-dissolved gas equilibrate depends on a number of factors known in the



art, including, for example, the surface area of the medium-gas interface, the viscosity of the medium, and the degree of agitation of the medium.

Pneumococci can be maintained in medium (e.g. liquid medium) in which the interface between the medium and any gas phase, if any, is minimized. In such culture systems, altering the content of the gas phase can have relatively little effect on the gas content of the liquid medium, owing to limited diffusion of gas from the gas phase into the liquid. In such systems, the gas content of the liquid medium can be influenced by the method used to prepare the medium. For example, substantially anaerobic liquid medium can be made by preparing a liquid medium, sterilizing it in an autoclave (the heat of which drives substantially all oxygen from the liquid), and cooling the autoclaved medium in an oxygen-free atmosphere, such as in a closed container through which a steady stream of oxygen-free gas is passed. Examples of suitable oxygen-free gases include pure argon, argon mixed with 5-10% CO<sub>2</sub>, pure nitrogen, or some combination of N<sub>2</sub>, Ar, and CO<sub>2</sub>. Where a very high degree of anaerobicity is desired ([O<sub>2</sub>] << 0.1%), the oxygen-free gas which passes over the medium as it cools can be passed through or over a heated copper coil or mesh, using methods known in the art. Of course, similar methods can be used for preparation of solid, gelatinous, and semi-solid media having a desired gas content.

CPS production can also be enhanced by selecting an appropriate pneumococcal variant and form as the inoculum used to seed the medium for which the oxygen content, carbon dioxide content, or both, is modulated. It is understood that different variants of pneumococci can generate structurally distinct CPS. The methods described herein can be used to enhance CPS production using any pneumococcal variant. It is furthermore understood that many pneumococci exhibit at least two phenotypic forms. These forms can include an opaque (O) form and a transparent (T) form, wherein the opaque form is generally characterized by producing a greater amount of CPS. Thus CPS production can be further enhanced by selecting, as an inoculum, a form of a variant of a pneumococcus characterized by greater CPS production.

CPS produced using one or more of the methods described herein can be used (alone or in combination with other pneumococcal CPS species) to make pneumococcal vaccines and other immunogenic preparations using methods known in the art. Such methods generally involve separating the CPS from pneumococcal cells, optionally killing remaining pneumococcal cells, and combining the CPS with a pharmaceutically acceptable carrier (and,

optionally, an immunological adjuvant). Such preparations can be administered to an animal for the purpose of enhancing the immune response of the animal to infection by a pneumococcus.

Because pneumococcal CPS is believed to enable pneumococci to elude immune defenses in animals (e.g. humans), methods of inhibiting CPS production can be used to alleviate pneumococcal infections in animals. Pneumococcal infections (and complications arising therefrom) which can be alleviated in this manner include pneumonia (particularly pneumococcal pneumonia), bacteremia, sepsis, meningitis bacterial endocarditis, streptococcal exudative pharyngitis, cellulitis, and visceral abscesses.

It has been discovered that increasing the oxygen content in the environment decreases pneumococcal CPS production, thereby increasing the susceptibility of the pneumococci to the immune system. Similarly, it has been discovered that decreasing the carbon dioxide content in the environment decreases pneumococcal CPS production.

Pneumococcal infections and their side effects and complications can be alleviated by maintaining an animal afflicted with such an infection in contact with a gas having a super-atmospheric concentration of oxygen. Alternatively, the oxygen tension at the site of the infection can be increased (e.g. by providing pure oxygen or sterilized air directly to an infection site {e.g. a visceral abscess involving a pneumococcus} located within an animal body), relative to the normal oxygen tension at the site. For example, when the body site is the lungs (e.g. as with pneumococcal pneumonia), the normal oxygen tension is that of normal air. Pneumococcal pneumonia can be alleviated by providing a supra-atmospheric concentration of oxygen to the patients lungs using, for example, a respirator or a standard oxygen mask.

Pneumococcal infections and their side effects and complications can also be alleviated by decreasing the carbon dioxide tension at the site of infection in an animal below the carbon dioxide tension that normally occurs at such infection sites, and preferably below the carbon dioxide tension that normally occurs at that body site, even in the absence of pneumococcal infection. Decreasing the carbon dioxide tension at an internal body site other than the lungs can involve providing a flow of sterile gas through, over, or past the body site. When the site of infection is the lungs, carbon dioxide tension can be reduced by increasing the respiration rate, either by voluntary action of the patient or artificially (e.g. using a ventilator or respiration-quickeners drugs).

As described in greater detail in the example, increased CPS production in pneumococci is correlated with low expression of the *cpsD* gene and with a low degree of phosphorylation of CpsD protein. Production of CPS can therefore be enhanced by agents which increase expression of *cpsD*, increase the degree of phosphorylation of CpsD, or both. Conversely, production of CPS can be inhibited by agents which inhibit or reduce expression of *cpsD*, inhibit phosphorylation of CpsD, enhance de-phosphorylation of phosphorylated CpsD, or some combination of these. As discussed above, decreasing production of CPS in pneumococci involved in an infection in an animal can render those pneumococci more susceptible to attack by the animal's immune system.

The invention includes methods of assessing whether a test compound is an inhibitor of pneumococcal CPS production and methods of assessing whether a test compound is an enhancer of pneumococcal CPS production. In each of these methods, pneumococcal cells are maintained in the presence of the test compound and, separately but preferably identically, in the absence of the test compound. A direct effect of the test compound on CPS production can be assessed by assessing the amount of CPS produced by cells in the presence and absence of the test compound. Alternatively, the level of expression of *cpsD* (assessed by measuring production of either the corresponding RNA or the corresponding protein) or the degree of phosphorylation of CpsD (assessed by measuring either the number of phosphorylated tyrosine residues present in CpsD or the fraction of CpsD having at least one phosphorylated tyrosine residue) is assessed, and correlated with inhibition or enhancement of CPS production, as discussed above.

## References

Publications referred to in this application are as follows.

- Arrecubieta et al., 1995, Gene 167:1-7  
Austrian et al., 1966, J. Bacteriol. 92:1281-1284  
Auzat et al., 1999, Mol. Microbiol. 34:1018-1028  
Avery et al., 1931, J Exp. Med. 54:73  
Avery et al., 1944, J Exp. Med. 79:137-157  
Caparon et al., 1992, J. Bacteriol. 174:5693-5701  
Chen et al., 1988, Gene 164:155-164  
Cundell et al., 1995, Nature 377:435-438

- Cundell et al., 1995, *Infect. Immun.* 63:757-761
- Gibson et al., 1993, *Infect. Immun.* 61:478-485
- Hammerschmidt et al., 1996, *Mol. Microbiol.* 20:1211-1220
- Howden, 1976, *J. Clin. Pathol.* 29:50-53
- 5 Iannelli et al., 1999, *J. Bacteriol.* 181:2652-2652
- Ilan et al., 1999, *EMBO J.* 18:3241-3248
- Kim et al., 1998, *J. Infect. Dis.* 177:368-377
- Kim et al., 1999, *Infect. Immun.* 67:2327-2333
- Knecht et al., 1970, *J. Exp. Med.* 132:475-487
- 10 Levin et al., 1998, *Mol. Microbiol.* 30:209-219
- MacLeod et al., 1950, *J. Exp. Med.* 92:1-9
- Modde, 1978, *Experimentia* 34:1285-1286
- Neufeld, 1902, *Z. Hyg. Infektionskr.* 40:54
- Raz et al., 1997, *Clin. Infect. Dis.* 24:1164-1168
- 15 Ring et al., 1998, *J. Clin. Invest.* 102:347-360
- Rosenow et al., 1997, *Mol. Microbiol.* 25:819-829
- Saluja et al., 1995, *Mol. Microbiol.* 16:215-227
- Schrager et al., 1996, *J. Clin. Invest.* 98:1954-1958
- Sellin et al., 1995, *Microb. Pathogen.* 18:401-415
- 20 St. Geme III et al., 1991, *Infect. Immun.* 59:1325-1333
- Stevenson et al., 1996, *J. Bacteriol.* 178:4885-4893
- Throup et al., 2000, *Mol. Microbiol.* 35:566-576
- Tomasz, 1964, *Bacteriol. Proc.* 64:29
- Tuomanen et al., 1995, *New Eng. J. Med.* 332:1280-1284
- 25 Vincent et al., 1999, *J. Bacteriol.* 181: 3472-3477
- Wani et al., 1996, *Infect. Immun.* 64:3967-3974
- Watson et al., 1990, *Infect. Immun.* 58:3135-3138
- Weiser, 1998, *Microb. Drug Resist.* 4:129-145
- Weiser et al., 1994, *Infect. Immun.* 62:2582-2589
- 30 Weiser et al., 1999, *Infect. Immun.* 67:3690-3692
- Weyand et al., 2000, *J. Biol. Chem.* 275:3192-3200

### Example

The invention is now described with reference to the following Example. This Example is provided for the purpose of illustration only, and the invention is not limited to this Example, but rather encompasses all variations which are evident as a result of the teaching provided herein.

#### Oxygen Dependence of Capsular Polysaccharide Expression by *Streptococcus pneumoniae* is Associated with Post-Translational Modification of CpsD

The experiments presented in this Example demonstrate that differences in opacity phenotype among pneumococci (i.e. O-form versus T-form) are affected by environmental concentrations of oxygen, and that anaerobic growth conditions such as may occur in pneumonia influence the ability of O-form pneumococci to increase expression of CPS and evade immune clearance.

The materials and methods used in the experiments presented in this Example are now described.

#### Bacterial Strain and Growth Conditions

Strains of *S. pneumoniae* used in this study are described in Table I and included previously described O and T variants of clinical isolates P303 (type 6A), P324 (type 6B), P68 (type 18C) and P10 (type 9V), as described (Kim et al., 1998; Weiser et al., 1994). Bacteria were grown in non-sealed vessels in a semi-synthetic (C+Y medium, pH 8.0) or tryptic soy medium without shaking at 37°C, as described (Tomasz, 1964). Broth cultures were plated onto standard tryptic soy agar (TSA) plates containing 1% (w/v) agar, onto which 5000 units of catalase (obtained from Worthington Biochemical, Freehold, NJ) was spread. Inoculated media were incubated at 37°C in a candle extinction jar unless otherwise specified. Colony morphology was determined on this TSA medium under magnification and oblique, transmitted illumination, as described (Weiser et al., 1994).

Table I

Reactivity of Pneumococcal Strains and Mutants

with a Monoclonal Antibody which Binds Specifically with Phosphotyrosine

Strain	Encapsulation		Mucoidy		Characteristics/Genotype	Phenotype <sup>7</sup> Mab 4G10(+/-)	Reference
	+/ -	type	aerobic	anaerobic			
P303	+	6A	No	Yes	clinical isolate	+	(Kim et al., 1998)
P324	+	6B	No	Yes	clinical isolate	+	(Kim et al., 1998)
P68	+	18C	No	Yes	clinical isolate	+	(Kim et al., 1998)
P10	+	9V	No	Yes	clinical isolate	+	(Weiser et al., 1994)
D39	+	22	No	Yes	clinical isolate	+	(Avery et al., 1944)
R6x	-		No	No	D39( $\Delta cps24-cps2H$ )	-	(Iannelli et al., 1999)
SIII	+	3	Yes	Yes	clinical isolate	-	(Avery et al., 1944)
P138	+	3	Yes	Yes	R6x x SIII DNA	-	(Saluja et al., 1995)
P728	+	2	No	Yes	R6x x D39 DNA	+	This Example

<sup>7</sup> For each strain/mutant the O phenotype grown in the presence of oxygen was tested. '+', indicates reactivity with a single band of 25-27 kD.

Environmental carbon dioxide concentration was controlled under aerobic conditions using a CO<sub>2</sub> incubator.

Anaerobic growth conditions were obtained using the BBL GasPak™ system according to the manufacturer's instructions

(Becton Dickinson, Cockeysville, MD). In some experiments, the sodium bicarbonate component of the system was

employed in order to generate a 10% carbon dioxide atmosphere, and in other experiments, it was not. After harvesting the bacteria, the pH of the growth medium was measured to confirm that it was not affected by these differing culture conditions.

Analysis of clinical specimens was performed using similar methods. A total of 502 patients afflicted with meningitis were examined, of whom approximately 20% had bacteriologically proven pneumococcal meningitis. A

nasopharyngeal swab sample was collected from patients in whom a presumptive clinical diagnosis of pneumococcal meningitis had been made. This sample was plated immediately onto both 5% sheep's blood agar and tryptic soy agar containing 5000 units of catalase, and the plates were incubated at 37°C in an air atmosphere containing 5% CO<sub>2</sub>. Cerebrospinal fluid (CSF) samples were also plated on both blood agar and transparent plates, as were cultured patient blood samples in which pneumococci were observed following standard aerobic incubation for up to 48 hours. Initially, isolates which exhibited typical morphology on blood agar were confirmed as being pneumococci by Gram stain and Quellung reaction. All isolates were stored at -80°C in bacterial preservers, and colony morphology was determined as described herein. Statistical differences between rates of T and O phenotypes in nasopharyngeal and invasive site cultures were examined using Fisher's Exact Test.

#### Genetic Transformation

Encapsulated and non-encapsulated pneumococci were made competent for natural transformation as described (Weiser et al., 1999). Mutations in two-component signal transduction systems (TCSTSs) were transformed into strain P303 by selection of colonies from medium comprising erythromycin (1 microgram per milliliter). Encapsulated transformants were screened for altered colony morphology, and expression of CPS confirmed by the Quellung reaction using type-specific antisera (obtained from Statens Seruminstitut, Copenhagen, Denmark).

#### Quellung Reaction

Pneumococcal capsules were visualized in bacteria grown to mid-log phase in semi-synthetic medium under various conditions. For the Quellung reaction, an equal volume of culture and a composition comprising type 6 anti-serum and 1% (w/v) methylene blue obtained from the Statens Seruminstitut (Copenhagen, Denmark) were mixed on a glass slide for one minute, as described (Neufeld, 1902).

#### Quantitation of CPS

O- and T-form pneumococcal variants were grown in the semi-synthetic

medium to mid-log phase ( $A_{620} = 0.3$ ) or for 16 hours (at which time the cells were in the stationary phase). Cells were harvested by centrifugation at  $2000 \times g$ , washed in phosphate-buffered saline (PBS), sonicated for three 10-second intervals at  $0^{\circ}\text{C}$ , and stored at  $-20^{\circ}\text{C}$ . A capture ELISA technique was used to determine quantities of CPS present in variants grown under selected conditions, as described (Kim et al., 1998). Type-specific rabbit anti-serum (obtained from Statens Seruminstitut, Copenhagen, Denmark) was used at a dilution of 1:5,000 in 0.05 molar  $\text{Na}_2\text{CO}_3$  (pH 9.6), and was fixed overnight at room temperature to the walls of wells in microtiter plates. Between each incubation step, the plate was washed five times with Tris buffer (comprising 10 millimolar Tris, 150 millimolar NaCl, 0.05% Brij™ 35, and 0.02% (w/v) sodium azide). Brij™ 35 (polyoxyethylene(23) lauryl ether  $\text{C}_{12}\text{H}_{25}(\text{OCH}_2\text{CH}_2)_{23}\text{OH}$ ) is a detergent. Purified CPS obtained from type 6B, 6A, 18C or 9V pneumococci was used at a known concentration, and was purchased from the American Type Tissue Collection (Rockville, MD) for use as a standard. CPS in sonicated cell samples was detected using monoclonal antibodies designated HASP 4 (which binds specifically with type 6A and 6B CPSs), HASP 22 (which binds specifically with type 18C CPS), and HASP 33 (which binds specifically with type 9V CPS), and were used at a concentration determined in pilot experiments. Binding of monoclonal antibodies and CPS was detected using antisera which reacts specifically with mouse IgM and which is conjugated with alkaline phosphatase. This reagent was used as described (Kim and Weiser, 1998). Total cellular protein determination was carried out with sonicated cell extracts using the micro-bicinchoninic acid kit according to the manufacturer's directions (Pierce Chemical Co., Rockford, IL). The amount of CPS in the supernatant fraction was based on protein concentration in the corresponding cell sonicate fraction (i.e. in order to normalize CPS content on a per-unit-protein basis).

The capture ELISA method used to compare amounts of total teichoic acid in cell sonicates has been described (Kim et al., 1998). All experiments were performed in duplicate, and repeated at least three times. Results are expressed as



mean values per total cellular protein concentration.

#### Western Analysis

Bacteria were grown on tryptic soy agar supplemented with catalase as described above. After growth under selected conditions for 16 hours at 37°C, cells were removed from the surface using a sterile Dacron™ swab, re-suspended in PBS, and washed in PBS in order to adjust the cell density such that  $A_{620} = 0.5$ . After centrifuging, pelleted cells were re-suspended in Laemmli gel loading buffer and heated to 100°C for 5 minutes. The samples were then separated by SDS-PAGE on 12.5% (w/v) polyacrylamide gels, and then transferred to Immobilon-P™ membranes as described (Wani et al., 1996).

Immunoblotting was performed using a monoclonal antibody designated 4G10 (Upstate Biotechnology Inc., Waltham, MA) at a dilution of 1:2000 in TSBP buffer (Wani et al., 1996), and reactivity of blotted samples with this antibody was detected using mouse IgG anti-sera conjugated with alkaline phosphatase as described (Kim et al., 1999). Loading of approximately equal numbers of bacteria was confirmed by immunoblotting of duplicate membranes using previously described antisera raised against whole pneumococci (Wani et al., 1996).

#### Northern Analysis

Total RNA was isolated from O and T variants of strain P303 cells grown to mid-log phase in semi-synthetic medium under atmospheric and anaerobic conditions and purified as described (Weyand et al., 2000). Following separation of RNA on a formamide gel, ethidium bromide stained RNA was photographed and the image was digitized for comparison with RNA size markers. The RNA was transferred to a membrane using the VacuGene™ XL System according to the manufacturer's instructions (Pharmacia LKB Biotechnology, Uppsala, Sweden). The membrane was pre-hybridized in a solution comprising 0.5 molar NaPO<sub>4</sub> at pH 7.2, 1.5 millimolar EDTA, and 7% (w/v) SDS for 15 minutes at 65°C. The probe was prepared from an internal fragment of the *cps4D* gene, and was amplified by PCR using primers having

the following sequences:

5'-CCGGAATTCG TACAAATATA CAGTTGAGCG GAGATAAAC-3' (SEQ ID NO: 1) and

5'-CGCGGATCCT GTTGCTGTTA CCAAGATGGA CG-3' (SEQ ID NO: 2)

and genomic DNA obtained from a type 4 strain. The strain is the same strain used in whole genome sequencing by the Institute for Genomic Research. The PCR product was digested using restriction endonucleases *Bam*HI and *Eco*RI, and then cloned into a vector having transcriptional terminators flanking the polylinker to allow cloning of streptococcal sequences. This vector was constructed from pJDC9 by insertion of the blunt ended kanamycin resistance cassette of pUK4K (Pharmacia, Upsalla, Sweden) into a blunt ended *Cla*I site to allow selection of this marker in *E. coli* (Chen and Morrison, 1988). The *cps4D* fragment was inserted into *Bam*HI and *Eco*RI digested vector and transformed into *E. coli* strain DH5 $\alpha$ . Total RNA was extracted from pneumococcal O and T variants of strain P303 grown to mid-log phase in tryptic soy medium under atmospheric and anaerobic conditions.

The results of the experiments presented in this Example are now described.

#### Selection for Phenotypic Variants in Humans

In order to test whether selection occurs for different pneumococcal phenotypes in carriage and bacteremia in humans, paired isolates of the same serotype were obtained from the nasopharynx and blood of patients who exhibited signs of sepsis. It was necessary to obtain paired isolates, owing to strain-to-strain heterogeneity in colony morphology unrelated to opacity. *Pneumococcus* could not be isolated from the nasopharynx of bacteremic patients once antibiotic treatment had been initiated. Cultures of the nasopharynx and blood were therefore obtained substantially simultaneously. This limitation required that the study be carried out in a geographic location having a high incidence of pneumococcal bacteremia, in order that a sufficient numbers of paired isolates could be obtained.

Blood and nasopharynx isolates were obtained from 19 adult patients in Blantyre, Malawi, and were only considered as paired isolates if the isolates were subsequently shown to be of the same type by the Quellung reaction using type specific antisera. The majority of the paired isolates were type 1, the most common type in this location, as indicated in Table II. The majority of patients also tested positive for infection with the human immunodeficiency virus, which is believed to account for the high incidence of invasive pneumococcal disease among these patients. Of 19 paired isolates, 17 (89%) were of the T phenotype in the nasopharynx, whereas 12 (63%) were of the O phenotype in the blood. Of the ten paired isolates in which the phenotype of pneumococci obtained from the two sites were discordant, all exhibited a more T-like phenotype in the nasopharynx ( $P<0.001$ ). This demonstrates that in general there is a selection for phenotypic variants that results in the presence in the blood of a more O-like phenotype derived from among the predominately T-like population in the nasopharynx in natural bacteremic infection.

Table II  
Opacity Phenotype of Isolates Obtained from  
Human Carriage and Invasive Infections

Colony Phenotype		No. of Patients	Types (No.)	HIV Status		
Nasopharynx	Blood/CSF <sup>1</sup>			+	-	N/A <sup>2</sup>
T	T	7	1(4),4,18,19	5	1	1
O	O	2	1(2)	1	0	1
O	T	0				
T	O	10	1(4),4(2),6,12, 15, 22	5	1	4

Notes: <sup>1</sup> 4/19 invasive isolates were obtained from cerebrospinal fluid rather than blood.

<sup>2</sup> N/A means clinical status not available.

#### Effect of Oxygen on Amounts of CPS

Host and bacterial factors that could promote selection of O variants during infection and T variants during carriage were investigated. It was hypothesized that lower oxygen tension of the sort that would be encountered in consolidated lung would promote a transition to from the T to the O phenotype. Growth of a type 6A clinical isolate, P303, in reduced concentrations of oxygen had no effect on the rate of spontaneous switching from the T- to the O-form. Growth under anaerobic conditions (in the presence of an elevated concentration of carbon dioxide), however, was associated with a shift to a larger and more mucoid colony morphology that was particularly marked for the O variant, as shown in Figure 1A.

Because pneumococci exhibiting the O phenotype express greater amounts of CPS than those exhibiting the T phenotype, it was considered possible that the greater colony size associated with the O form was a result of increased production of this material (Kim et al., 1998). In initial studies, the refractile zone of CPS surrounding bacterial colonies was visualized using the Quellung reaction and type 6 antisera, as shown in Figure 1B. This zone was larger for the O variant grown under anaerobic conditions in the presence of 10% carbon dioxide, compared to either growth of the same phenotype in the presence of oxygen or growth of the T variant under any of the conditions tested including the absence of oxygen. In contrast, when the bacteria were cultured under atmospheric conditions, a zone of capsular material could not be detected around colonies of T-form pneumococci. This result confirmed the ability of the O form to synthesize increased quantities of CPS, and indicated that reduced oxygen tension, higher carbon dioxide tension, or both promotes increased CPS production.

The effect of environmental oxygen and carbon dioxide concentration was assessed quantitatively using an assay developed for measuring amounts of CPS, as indicated in Figure 2 (Kim et al., 1998). The amounts of CPS per milligram of total cellular protein, as assessed using the capture ELISA described herein, correlated with colony surface area and with capsular volume values calculated based on visualization of zones using the Quellung reaction and with colony surface area, as indicated in Table III. O-form bacteria at either mid-log phase or stationary phase growth exhibited increased amounts of cell-associated CPS compared to the T-form organisms. Growth of the O type 6A variant under anaerobic conditions in the presence of 10% CO<sub>2</sub> caused a 7.9-fold rise in the quantity of CPS produced, compared to CPS production in the same cells cultured under atmospheric conditions. Compared to T variants grown under the anaerobic conditions in the presence of 10% CO<sub>2</sub>, the O variant made 29 times as much CPS. Similar results were obtained using O and T isolates obtained from two unrelated clinical isolates (i.e. using types 6B and 18C).

Table III  
Characteristics of Pneumococci Grown Under Various Conditions

		Colony Morphology <sup>3</sup>					
		O-form			T-form		
		O <sub>2</sub> (%)					
	CO <sub>2</sub> (%)	<0.1	3	10	<0.1	3	10
Average Colony Area (mm <sup>2</sup> ) <sup>4</sup>		3.53	7.42	169	1.02	5.15	12.3
Volume Occupied by a Single Cell, including Capsule(μm <sup>3</sup> ) <sup>5</sup>		3.64	6.85	63.5	UD	4.62	10.6
Capsular Polysaccharide (ng/μg total protein) <sup>6</sup>		126	221	997	35.4	19.4	34.2

<sup>3</sup>For O and T variants of the same type 6A clinical isolate.

<sup>4</sup>These values are based on colonies observed after 16 hours growth. Values represent the average of determinations made using three single well isolated colonies.

<sup>5</sup>These values are based on capsular material revealed using the Quellung reaction and the formula for the volume of a spherical ellipsoid,  $V=(\pi/6)LW^2$ . Values represent the average of determinations for three diplococcal forms divided by two to correspond to a single cell. "UD" means that a zone of capsular material was not detectable.

<sup>6</sup>These values are based on capture ELISA assessment of organisms grown in liquid culture at mid-log phase. Values are the mean of two separate determinations.

Production of CPS in culture supernatant was assessed for type 18C pneumococci after growth to stationary phase. The observation that a greater amount of polysaccharide was produced in the culture supernatant of the O-form variant as the concentration of oxygen was decreased and as the concentration of carbon dioxide was increased indicates that increased CPS production was attributable to increased synthesis of CPS by cells under decreased oxygen/increased carbon dioxide conditions, rather than being attributable to decreased release of CPS from cells under increased oxygen/decreased carbon dioxide conditions. A type 9V isolate was used to determine whether increased synthesis of CPS was attributable by decreased oxygen or increased carbon dioxide. Type 9V bacteria grown to stationary phase in the presence of 10% carbon dioxide exhibited 12-fold greater CPS production in the absence of oxygen than the same cells grown in the presence of 10% carbon dioxide and in the presence of oxygen. This confirmed that the oxygen tension, rather than carbon dioxide tension, is the predominant environmental factor affecting the degree of CPS production.

#### Changes in CPS Production Correlate with Changes in *cpsD*/CpsD

The next phase of the study addressed the mechanism by which the effect of oxygen on CPS production is mediated. Involvement of a two-component

signal transduction system for sensing and transducing oxygen tension/presence was examined. Previously described marked mutations in 11 of the 12 of two-component signal transduction systems found in the genome of a type 3 isolate of were transformed into strain P303, as described (Throup et al., 2000). 10 constructs harboring mutations in response regulator homologues were made, as were 7 constructs harboring mutations in histidine kinase homologues. For each of the 17 mutant homologues tested in P303, there was no effect on increased colony size or zone of capsule formation, as assessed using the Quellung reaction, in experiments in which the cells were grown under anaerobic conditions. This result indicated that it is unlikely that the effect of oxygen is mediated through a TCSTS, although one of these systems in the pneumococcus could not be examined because the genes appear to be essential.

The genes in a locus known to be required for expression of CPS were examined next. Since the effect of oxygen on amounts of CPS was observed in strains of multiple types, genes conserved among different types were considered the most likely candidates. Among the genes in the capsule loci, only the first four, *cpsA-D*, are common to pneumococci of different types (Iannelli et al., 1999). Type 3 pneumococci are known to form mucoid colonies and to have large capsules, as assessed by the Quellung reaction, when grown under atmospheric conditions, as indicated in Table I (Knecht et al., 1970). Unlike all other pneumococcal types tested, type 3 strains failed to show an increase in the sizes of colonies or capsules when cultured under anaerobic conditions, relative to the sizes when cultured under atmospheric conditions. Based on this observation, differences in *cpsA-D* between the type 3 and loci of other types was determined.

Homologs of *cpsA*, encoding a putative transcriptional attenuator, and *cpsB*, encoding a protein of unknown function, are present in the type 3 capsulation locus (Genbank accession no. Z47210; Arrecubieta, 1995). The gene encoding CpsC in serotype 2 pneumococci is highly conserved in the type 3 capsulation locus, but the predicted CpsD in serotype 3 pneumococci is truncated following amino acid 69 (of

226). CpsC and CpsD are required for expression of the pneumococcal capsule and together are homologous to a single protein (Wzc) expressed in *Escherichia coli* that is involved in chain length regulation and export of the extracellular polysaccharide designated colanic acid (Morona et al., 1999; Stevenson et al., 1996).

5 In *E. coli*, Wzc undergoes reversible autophosphorylation at a tyrosine residue (Vincent et al., 1999). A monoclonal antibody which is designated 4G10 which binds specifically with phosphorylated tyrosine residues was used to determine by Western analysis that phosphorylated tyrosine is present in the pneumococcus. A single band of approximately 26 kD, the predicted size of CpsD, was present in whole cell lysates of the type 6A isolate. A single band of the same size was also seen in whole cell lysates of the types 6B, 18C, and 9V strains used in this study, but was absent from the type 3 pneumococci (which have a truncated CpsD). These observations indicated that CpsD is phosphorylatable at a tyrosine residue. Further evidence that 4G10 was recognizing CpsD having a phosphorylated tyrosine residues was obtained by comparing strains D39 (an non-encapsulated mutant) and R6x (a strain having a 7504 base pair deletion spanning *cps2A-H*, of which only *A-D* are common to other types; Iannelli et al., 1999). The mutation in R6x-type pneumococci was corrected in some experiments by transforming the bacteria using DNA obtained from either the (type 2) D39 parent strain or a type 3 strain to yield an encapsulated strain with either type 3 or 2 capsule in the D39 type 2 genetic background.

20 Failure of 4G10 to react with R6x and the type 3 R6x transformant and reaction of the antibody with the type 2 R6x transformant confirmed that expression of the protein corresponding to this band requires one of the first four common genes in the capsulation locus and an intact copy of *cpsD*. It was determined that the 4G10 reactive protein is not likely to be CpsA or B based on size. There are only 15 conservative amino acid changes between type 2 and 3 CpsC, of which none involve tyrosine. The lack of the 4G10 reactive band in the type 3 strain indicated that the



4G10-reactive protein is not CpsC. It was therefore concluded that CpsD protein comprises a phosphorylatable tyrosine residue in the pneumococcus.

5 The effect of growth under various concentrations of oxygen and carbon dioxide on tyrosine phosphorylation of CpsD was examined. Lysates of whole cells of the O and T forms of the type 6A pneumococcal isolate designated P303 which had been grown under various concentrations of oxygen and carbon dioxide were adjusted to an equivalent density and examined by Western analysis using the phosphotyrosine-specific monoclonal antibody 4G10. The results of these experiments are shown in Figure 3. A single band of the expected size for CpsD was detected in the O variant grown in the presence of oxygen. There was no reactivity with the extract obtained from an approximately equal number of cells grown anaerobically, as indicated in lane 1 of Figure 3. There was no apparent effect of differences in carbon dioxide tension from <0.1 to 10%, as indicated by the results in lanes 2-4 of Figure 3. Under all conditions tested (oxygen <0.1% to 21% and carbon dioxide <0.1% to 10%), reactivity of the antibody with cell extracts of the T variant was faint. Similar results were obtained using other strains. It was therefore concluded that tyrosine phosphorylation of CpsD is affected by opacity phenotype and requires growth in the presence of oxygen.

20 Difference in tyrosine phosphorylation can affect the activity of CpsD and account for decreased expression of CPS in O pneumococci in the presence of oxygen. Neither O nor T pneumococci grown anaerobically express phosphorylated tyrosine; however the two phenotypic forms exhibit large differences in the degree of CPS production.

25 Northern analysis was used to determine if differences between O and T variants were due to differences in the level of transcription of *cpsD*. The results of these experiments are shown in Figure 4. Total cellular RNA was obtained from O and T forms of pneumococcal strain P303 grown either under atmospheric conditions or anaerobically in the presence of 10% carbon dioxide. The RNA was probed using a

cloned fragment of *cpsD*. Quantitative differences in transcriptional activity were determined by assessing hybridization of radio-labeled probe with *cpsD* in mRNA and adjusting these values for the total amount of RNA present in the hybridization assay mixture. These experiments demonstrated that oxygen concentration had no substantial effect on the level of *cpsD* transcription. However, *cpsD* was transcribed at a 3.4-fold greater level in T-form cells, relative to O-form cells. It was therefore concluded that transcriptional regulation of *cpsD* determines the opacity phenotype of pneumococci.

Without wishing to be bound by any particular theory of operation, it is believed that CpsD regulates CPS production. Correlation between differences observed in the degree of tyrosine phosphorylation of CpsD and differences in CPS production support this theory. It is believed that CpsD functions as a tyrosine kinase, based in part on its amino acid sequence similarity to a tyrosine autophosphorylating enzyme in *E. coli* which is involved in chain length regulation and export of the extracellular polysaccharide colanic acid. Cps23FD has 30% identity and 49% similarity over 188 of 229 amino acids to Wzc. CpsD of serotype 23f pneumococcus contains an unusual carboxyl-terminal amino acid sequence (YGSYGNYGNY GKNKK; SEQ ID NO: 3) which contains a repetitive feature (YGX)<sub>4</sub> including tyrosine residues. This carboxyl-terminal region exhibits considerably greater amino acid sequence heterogeneity among pneumococcal variants than the remainder of CpsD. It is believed that the variability in CPS production among pneumococcal strains is attributable to the variability of this carboxyl-terminal portion among the strains, the sequence variation affecting the phosphorylat-ability of the protein. A number of other bacterial protein kinases have been identified and these have in common a C-terminus with a tyrosine-rich repetitive feature (Ilan et al., 1999). Inability to generate a pneumococcal strain harboring a mutation in *cpsD* while maintaining the ability of the strain to produce CPS is further evidence of the importance of this gene in CPS and capsule production.

The following model of a mechanism for regulating CPS production in

response to colony opacity phenotype and oxygen tension is proposed. The model involves transcriptional regulation of *cpsD* and post-translational modification of CpsD.

CpsD is a negative regulatory factor which act on genes involved in biosynthesis of pneumococcal type-specific CPS. Relatively low *cpsD* transcription accounts for the relatively high amounts of CPS expressed in O-type pneumococci under anaerobic conditions. Apart from transcriptional regulation of *cpsD*, which accounts for a significant proportion of CPS expression regulation, a second level of regulation is involved, namely phosphorylation or autophosphorylation of tyrosine residue(s) on CpsD. Phosphorylation of CpsD affects only the O variant and requires growth under aerobic conditions. Detectability of CpsD which is phosphorylated at one or more tyrosine residues only in the O variant may be due to increased phosphatase activity in T pneumococci. Tyrosine phosphorylation increases the negative regulatory activity of CpsD, such that phosphorylated CpsD decreases synthesis of CPS under aerobic conditions. As a result, less CPS is made by O variants under aerobic conditions than under anaerobic growth conditions. Relatively low CPS production in T-form pneumococci, even in the absence of appreciable tyrosine phosphorylation of CpsD, is attributable to increased expression of *cpsD* in T-form pneumococci.

What had previously been described as improved growth under anaerobic condition, may in fact be an effect of increased CPS synthesis resulting in larger colony size (Modde, 1978).

Homologues of CpsD with even greater similarity to Wzc are present in many other species of bacteria that express surface polysaccharides. Examples of such species include *Streptococcus agalactiae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Acinetobacter johnsonii*. Since capsules and their size are critical determinants of virulence, the ability to regulate amounts of CPS based on transcriptional and post-translation modification of this class of gene/protein may be

important in facilitating the ability of encapsulated bacteria to adapt to the differing requirements of colonization and infection.

The disclosure of every patent, patent application, and publication cited herein is hereby incorporated herein by reference in its entirety.

5

While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention can be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims include all such embodiments and equivalent variations.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2